Elucent Medical
Founded 2014 Β· 129 employees on LinkedIn Β· 2 known investors
Elucent develops precision-guided surgical technologies that use 3D spatial positioning to make surgical procedures less invasive and more effective. The company serves medical professionals and hospitals seeking to improve surgical outcomes and reduce patient recovery times.
Also known as Elucent Β· Elucent Medical Inc.
Founders & leadership
Investors Β· 2
Company profile
researched Aug 2026Elucent Medical is a medical device company that develops surgical guidance and navigation technology based on what it calls In-Body Spatial Intelligence (iSi). Its EnVisio system provides continuous, real-time 3D information on depth, distance and direction between a surgical instrument and an implanted tissue marker, allowing surgeons to locate and resect target tissue without additional verification steps or tool exchanges.
The EnVisio Smart Tool Suite comprises the SmartSensor, an attachable device that converts existing surgical instruments into tracked smart tools; the SmartClip, a permanently implantable soft tissue marker that emits differentiated positional signals with no minimum distance requirement between markers; the SmartSurface, a spatial field generator that measures data points across multiple planes and displays the 3D position of the clip and sensor without a separate hand-held localization probe; and SmartSupport, an on-demand virtual technical and clinical support service delivered over a HIPAA-compliant platform from a Minneapolis-based customer service team.
EnVisio is optimized for guiding breast cancer surgery, including localization of calcifications and bracketing of complex lesions, and its use has extended to other soft-tissue oncology procedures. The company has stated it is developing products aimed at margin-negative resection in lung and other soft-tissue applications that integrate with minimally invasive, video- and robotic-assisted platforms.
Business model
Elucent Medical manufactures and sells surgical navigation hardware and implantable markers to hospitals and health systems, combining a capital/console component (SmartSurface field generator and SmartSensor) with consumable implantable SmartClip markers, and provides an accompanying virtual clinical and technical support service (SmartSupport).
Traction
Elucent reported 25,000 lives impacted through EnVisio technology as of July 2025. Health systems announcing adoption include Froedtert & the Medical College of Wisconsin (August 2024) and Cuyuna Regional Medical Center (August 2024). The company received FDA Breakthrough Device Designation for the EnVisio X1 system in May 2025.
Latest developments
In 2025 the company received FDA Breakthrough Device Designation for the EnVisio X1 In-Body Spatial Intelligence System (May), announced 25,000 lives impacted through EnVisio (July), and launched the SmartSupport virtual support service (August). In January 2025 it secured $30 million in growth capital from Trinity Capital.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
The company positions EnVisio as a soft tissue localization platform for breast surgical navigation, with investors describing an aim to establish market leadership in breast navigation and to launch products in lung and other soft-tissue applications. A third-party data provider estimates annual revenue in the $25M-$50M range.
Elucent emphasizes that its sensor attaches to instruments surgeons already use rather than requiring a dedicated probe, that it delivers continuous true 3D positioning (depth, distance and direction) rather than intermittent readings, that it offers roughly five times the depth range of traditional localization methods, that performance is unaffected by metal instruments, hematoma, air or dense tissue, and that multiple SmartClips can be differentiated with no minimum distance requirement for bracketing.
Technology
The In-Body Spatial Intelligence platform combines materials engineering with an algorithm that continuously and simultaneously processes signals to determine the true 3D location of the implanted SmartClip marker relative to the tip of an instrument-mounted SmartSensor. The company states the system provides five times greater depth of field than traditional localization methods, supports differentiated signals from multiple SmartClips with no minimum separation distance, and is not affected by interference from surgical metal instruments, hematoma, air or dense tissue.
Go-to-market
The company sells through a direct commercial organization with dedicated sales operations, customer support and marketing functions, and expands via adoption announcements with individual hospitals and health networks. It supplements this with a virtual support offering during procedures and with awareness partnerships such as one with SurvivingBreastCancer.org.
Breast and soft-tissue oncology surgeons and the hospitals and health systems that employ them; reported users include Prisma Health, UCLA Health, SSM Health, Saint Francis Hospital, Fox Chase Cancer Center, Froedtert & the Medical College of Wisconsin, and Cuyuna Regional Medical Center.
Geography
Headquartered in Eden Prairie, Minnesota, with a facility opened there in August 2023 and a Minneapolis-based customer support team; a third-party directory lists employees only in North America.
History
A third-party directory lists a 2014 founding date. The company opened a new Eden Prairie, Minnesota facility in August 2023 with plans to add at least 30 jobs across R&D, quality, operations and manufacturing, closed a $42.5 million Series C in April 2024 led by Vensana Capital and RC Capital, received $30 million in growth capital from Trinity Capital in January 2025, obtained FDA Breakthrough Device Designation for EnVisio X1 in May 2025, and launched SmartSupport in August 2025.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 9
launches, deals, and filingsElucent Medical launched SmartSupport, an on-demand virtual technical and clinical support service delivered over a HIPAA-compliant platform by a Minneapolis-based customer service team.
Elucent Medical announced it had reached 25,000 lives impacted through its EnVisio technology.
Elucent Medical received Breakthrough Device Designation from the U.S. Food and Drug Administration for its EnVisio X1 In-Body Spatial Intelligence System.
Trinity Capital Inc. (NASDAQ: TRIN) committed $30 million in growth capital to Elucent Medical.
$30M source β
Cuyuna Regional Medical Center began offering the new breast cancer treatment technology.
Elucent Medical announced that the Froedtert & the Medical College of Wisconsin health network would offer its breast cancer surgical technology.
Elucent Medical announced the closing of a $42.5 million Series C round led by Vensana Capital and RC Capital with participation from existing investors, to fund development and commercialization of its EnVisio and SmartClip technologies. Greg Banker and Kirk Nielsen of Vensana Capital and Scott Steever of RC Capital joined the board.
$42.5M source β
Elucent Medical held a grand opening for a new facility in Eden Prairie, Minnesota, with plans to add at least 30 jobs over the following couple of years across research and development, quality, operations and manufacturing.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 8
primary sources listed
- Elucent Medicalelucent.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Elucent Medical do?
- Elucent Medical makes the EnVisio surgical guidance system, which adds real-time 3D tumor localization to standard surgical instruments.
- Who are Elucent Medical's investors?
- Elucent Medical's investors include RC Capital, Vensana Capital.